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Three-dimensional (3D) cell culture technology has under-
gone rapid development as an alternative to traditional 2D 
cell cultures.1 In vitro 3D culture systems promise more 
reliable and predictive tissue-like models for drug develop-
ment and substance testing.2–4 This has been emphasized in 
the recently published special theme issue of Advanced 
Drug Delivery Reviews (“Innovative Tissue Models for 
Drug Discovery and Development,” http://www.sciencedi-
rect.com/science/journal/0169409X/69-70).
Organ-like tissue models need to exhibit a certain degree 
of complexity to reflect the in vivo situation as closely as 
possible. With respect to this highly demanded complexity, 
bioprinting shows a great potential to produce artificial 3D 
tissues and organs.5–6 The advantage of this technology 
compared to standard tissue-engineering approaches is the 
exact positioning of cells and bioactives, such as signaling 
factors and matrix components (so-called bioinks), to obtain 
spatial control.7
To print 3D soft tissue–like structures, cells are either 
mixed with bioink and printed or printed separately as cell 
suspensions onto bioink. The 3D construct is assembled in an 
additive manner by printing layer by layer. Three different 
approaches are pursued for the printing of living tissue mod-
els: (1) laser-assisted bioprinting (LaBP), (2) inkjet printing, 
and (3) robotic dispensing (reviewed in Refs. 8–9). Besides the 
bioprinting instruments’ properties, the characteristics of the 
bioinks are of prime importance to obtain high-fidelity 
printed constructs. Therefore, much effort is actually been 
put into the development and characterization of bioinks that 
not only have to be printable and viscous enough to maintain 
the structure before polymerization but also have to provide 
the perfect extracellular matrix (ECM)-like environment.9–10 
Several naturally derived and synthetic hydrogel materials 
are commonly used as bioinks, such as alginate,11 gelatin,12 
collagen I,13 matrigel,14 fibrinogen,15 hyaluronic acid,16 aga-
rose,17 chitosan,18 and poly(ethylene) glycol (PEG).19 All of 
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Abstract
Cells grown in 3D are more physiologically relevant than cells cultured in 2D. To use 3D models in substance testing 
and regenerative medicine, reproducibility and standardization are important. Bioprinting offers not only automated 
standardizable processes but also the production of complex tissue-like structures in an additive manner. We developed 
an all-in-one bioprinting solution to produce soft tissue models. The holistic approach included (1) a bioprinter in a sterile 
environment, (2) a light-induced bioink polymerization unit, (3) a user-friendly software, (4) the capability to print in 
standard labware for high-throughput screening, (5) cell-compatible inkjet-based printheads, (6) a cell-compatible ready-to-
use BioInk, and (7) standard operating procedures. In a proof-of-concept study, skin as a reference soft tissue model was 
printed. To produce dermal equivalents, primary human dermal fibroblasts were printed in alternating layers with BioInk 
and cultured for up to 7 weeks. During long-term cultures, the models were remodeled and fully populated with viable and 
spreaded fibroblasts. Primary human dermal keratinocytes were seeded on top of dermal equivalents, and epidermis-like 
structures were formed as verified with hematoxylin and eosin staining and immunostaining. However, a fully stratified 
epidermis was not achieved. Nevertheless, this is one of the first reports of an integrative bioprinting strategy for industrial 
routine application.
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these polymers show distinct polymerization modes to pro-
duce stable scaffolds in an additive manner.9 But, until today, 
no hydrogel has been developed and commercialized for 
standardized bioprinting processes.
In Europe, since July 2013, it is mandatory by law to assess 
the potential hazard of cosmetic ingredients with in vitro skin 
models because animal tests are banned.20–21 Therefore, artifi-
cial skin is one of the best-characterized tissue models, and 
several validated models are currently commercially available. 
Also in drug development, these models are expected to sub-
stantially contribute to assessing systemic drug application on 
the skin and the effect of drugs to treat skin diseases or disor-
ders.22 Bioprinting technology is currently under investigation 
to produce in vitro skin to standardize the manufacturing pro-
cess. Lee et al.,23 in a primary study, showed the feasibility to 
print defined layers of human primary fibroblasts and keratino-
cytes in a collagenous matrix using the inkjet-based printing 
approach. The collagen I precursor solution was jetted and 
solidified on a pH change after addition of sodium bicarbonate 
by a nebulizer. In a follow-up study, Lee and coworkers24 opti-
mized the skin bioprinting approach using the human cell lines 
foreskin fibroblasts-1 (hFF-1) and keratinocytes (HaCaT). 
After culture of the HaCaTs at the air–liquid interface, the cells 
started to differentiate and to express epidermis-specific pro-
teins, such as N-cadherins. However, a fully stratified epider-
mis could not be achieved with cell lines.
Koch et al.25 used LaBP to build skin-like structures with 
cell lines from mouse fibroblasts (NIH3T3) and HaCaTs 
embedded in a collagen matrix transferred to a matrigel 
support. The models were characterized with histological 
analyses for the expression of several skin-specific proteins 
such as pan-cadherin, connexins, and laminin. In a subse-
quent study by Michael et al.,26 the printed skin construct 
was transplanted into a dorsal skinfold chamber in nude 
mice and fully integrated into the surrounding tissue. 
However, the usage of cell lines instead of primary cells 
was the main limitation of this study.
In this report, we developed an all-in-one-solution for a 
reproducible bioprinting process, including customized solu-
tions of a ready-to-use printable matrix (BioInk) combined 
with the commercialized bioprinter 3DDiscovery and a print-
ing protocol. In a proof-of-concept study, a skin model was 
developed as a soft tissue reference. Primary human dermal 
fibroblasts were printed onto BioInk layers. The printed der-
mis equivalents were long-term cultured, showing cell viabil-
ity and proliferation as well as the capability to remodel the 
matrix as verified by collagen type I expression. Moreover, 
the dermal models supported primary keratinocyte differen-
tiation. Printed skin equivalents were characterized histologi-
cally and demonstrated the feasibility to print skin-like 
constructs with two primary cell types.
Our integrative bioprinting strategy should contribute 
not only to standardizing the bioprinting process but also to 
producing tissue models on demand in a reproducible way 
for routine industrial application.
Materials and Methods
Cell Expansion
Human primary dermal fibroblasts (HDFa; Cascade Biologics, 
Invitrogen, Basel, Switzerland) were cultured in monolayer 
using Dulbecco’s Modified Eagle’s Medium (DMEM)/F12 
(Sigma-Aldrich, St. Louis, MO) supplemented with 10% 
fetal bovine serum (FBS; Gibco, Waltham, MA) (HDFa 
medium I). Human primary epidermal keratinocytes 
(HPEK; CELLnTEC Advanced Cell Systems, Bern, 
Switzerland) were cultured in CnT-57 proliferation medium 
(CELLnTEC) at 37 °C and 5% CO2. Media were exchanged 
every 3 days, and the cells were subcultured at 70–80% 
confluency. For the printing experiments, HDFas were used 
up to passage 6, and HPEKs up to passage 5.
Bioprinter
The bioprinting device 3DDiscovery (Fig. 1) consists of an 
x-y-z-axis positioning system with a tool charger equipped 
with four work stations and a building platform. The tool 
charger moves in the x- and z-axes. The building platform, 
at which cell culture vessels (e.g., well plates and inserts) 
are placed, moves in the y-direction. Each work station is 
equipped with an independently controllable printhead. 
Biomaterial (e.g., ECM molecules, cells, and signal mole-
cules) is provided in 3 ml disposable cartridges fixed onto 
the printhead with luer lock connections. Liquid dispensing 
with the cell-compatible printheads is controlled by electro-
magnetic microvalves based on inkjet technology and sterile 
compressed air with an accuracy of ±10 nl. To print under 
temperature-controlled conditions, a cartridge-cooling unit is 
integrated into the bioprinter. An ultraviolet (UV) light-
emitting diode (LED) unit (λ = 365 nm ± 10 nm) was inte-
grated to induce photopolymerization of the printable 
matrix BioInk.
Printing speed, frequency, as well as dispensed volume 
of each material are controlled by different parameters, 
such as dosing distance, valve opening time, and air pres-
sure (Table 1).
The bioprinting device is housed in a flow box permit-
ting work under sterile conditions. The 3DDiscovery is 
capable of printing in standardized cell culture plates 
(Society for Biomolecular Screening standards) and cell 
culture inserts.
The HMI (human–machine interface) software of the 
3DDiscovery bioprinter is the central tool to initialize and 
control the device as well as to define the printhead param-
eters (Table 1).
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The BioCAD (version 1.0-040) program provided with 
the 3DDiscovery bioprinter allows the easy drawing of 3D 
patterns with defined dimensions for further fabrication of 
printed tissues. Each layer to be printed is clearly defined 
with respect to the shape and pattern, thickness, material, 
and printhead used. For each material, detailed parameters 
(feed rate, thickness, pressure, etc.) have to be defined 
(Table 2). The printing sequence of the layers as well as the 
thickness of the designed model represent the last step of 
the BioCAD program before it is loaded in the HMI soft-
ware for the 3D model realization.
Sterility Test
To assure sterile printing conditions, every component in 
contact with printed tissue was sterilized. The flow box of the 
bioprinter was cleaned with 75% ethanol and further steril-
ized by UV light for 30 min. The components to be assem-
bled in the bioprinter, such as the disposable cartridges and 
the microvalves, were sterilized by autoclave and assembled 
in the pre-sterilized 3DDiscovery. Fibroblasts were expanded 
in monolayer cultures in HDFa medium I and detached by 
trypsin–EDTA before being printed or manually seeded in six 
well plates. The printing parameters used are summarized in 
Table 3, and the dispensing process was repeated 10 times 
per well (about 50,000 cells/well in a total volume of 100 µl). 
Fibroblast viability was determined with the Cedex cell 
counter (Cedex Innovatis; Roche, Basel, Switzerland), and it 
was compared to the viability of manually seeded fibroblasts 
(positive control). Printed as well as manually seeded fibro-
blasts were cultured for 14 days at 37 °C and 5% CO2 in 
HDFa medium I (6 ml/well) without medium changes. 
Sterility was checked under the microscope.
BioInk
The printable ECM-like BioInk was developed and synthe-
sized in collaboration with biologists and chemists at the 
Zurich University of Applied Sciences (ZHAW). To commer-
cialize the BioInk, the production process was standardized, 
and the product is now being sold by regenHU Ltd. It is a 
ready-to-use, sterile, cell-compatible and -degradable solution. 
For fast polymerization, a cytocompatible photo-initiator is 
Table 1. HMI Printing Parameters.
Parameter Value
Dosing distance 0.005–5.000 mm
Valve opening time 100–50,000 µs
Air pressure Up to 6 bar
Figure 1. Image of the bioprinting 
device called 3DDiscovery used in 
the present study. (A) To print under 
sterile conditions, it is enclosed into 
a flow box. (B) A close-up view 
of the 3DDiscovery: (1) flow box; 
(2) 3DDiscovery; (3) air pressure 
regulators; (4) printheads; (5) tool 
charger; (6) building platform; and (7) 
console.
Table 2. BioCAD Material-Specific Printing Parameters.
Property Value
Feed rate 0.5–40.0 mm/s
Thickness 0.01–10.00 mm
Laser Yes or no
Pressure Yes or no
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integrated that induces cross-linking of the chemically defined 
PEG-based BioInk on illumination at 365 nm ± 10 nm.
Fabrication of Dermal-Equivalent Models
Technical aspects and printing parameters. The BioInk solu-
tion was printed with the CF-300N printhead, which can 
dispense liquids with a viscosity of up to 1000 mPa . s . The 
printhead is composed of (1) a 3 ml disposable cartridge; 
(2) a microvalve CF-300, which is used for contact dispens-
ing with a nozzle diameter of 0.3 mm and a stroke of 0.1 
mm; and (3) a needle CF-300 with an inner diameter of 0.3 
mm. The printing temperature was set at 20 °C with the 
integrated cartridge cooler system to maintain constant 
printing conditions.
The fibroblasts were collected at a concentration of 
9.0×106 cells/ml into 3 ml disposable syringes and were dis-
pensed by jetting with the microvalve CF-300 nozzle diam-
eter of 0.10 mm and stroke of 0.06 mm. The printing 
parameters defined in the HMI and BioCAD software are 
summarized in Table 4.
Printing scheme and generation of 3D dermal-like models. The 
3D dermis equivalent was constructed using the layer-by-
layer approach. The 2D pattern of the structure was designed 
by the BioCAD software. The software allows the definition 
of printing direction and layer thickness. Figure 2 shows the 
BioInk printing pattern as an angular spiral with external 
dimensions of 6×5.5 mm (Fig. 2A). BioInk layer thickness 
was set at 0.05 mm, and the first seven layers of BioInk were 
alternated with seven layers of printed cells (Fig. 3). Fibro-
blasts were printed in the same pattern as the BioInk with 
dimensions of 5×4.5 mm (Fig. 2B). The last printed cell layer 
was covered with an additional layer of BioInk to maintain 
the cells inside the model. For further experiments, including 
keratinocytes seeding, a cylindrical pattern consisting of 
seven BioInk layers with a radius of 2.7 mm was printed on 
top of the dermal model to provide a confined area for kerati-
nocytes seeding. BioInk layer thickness was set at 0.05 mm 
(Figs. 2C and 3). Figure 3 shows a cross-section (Fig. 3A) 
and a 3D view (Fig. 3B) of the printed structure. Each BioInk 
layer was polymerized immediately after printing with the 
integrated UV system at a wavelength of 365 nm ± 10 nm 
and a feed rate of 5 mm/s. The height of the entire model was 
0.75 mm (0.40 mm of dermal part and 0.35 mm of cylindrical 
part).
The multilayered structures were printed directly on 
hydrophilic PTFE (polytetrafluoroethylene) cell culture 
inserts with 0.4 µm pore size (Millipore, Billerica, MA). 
The inserts containing the printed samples were transferred 
in six well plates and submerged in 6 ml of HDFa medium 
I supplemented with 1% penicillin–streptomycin (Sigma-
Aldrich) and 0.1% fungizone antimycotic (Gibco) (HDFa 
medium II). The dermal models were cultured for up to 7 
weeks at 37 °C and 5% CO2, and medium was changed 
every 2–3 days.
Cell Compatibility of Photopolymerization 
Process
To verify the cell compatibility of the BioInk polymeriza-
tion process, a cyclobutane pyrimidine dimer (CPD) 
enzyme-linked immunosorbent assay (ELISA) was per-
formed. CPD formation is one of the predominant types of 
Table 3. Printing Parameters to Verify the Sterility of the Cell-
Printing Process.
Software Parameter Value
HMI Dosing distance 0.30 mm
 Valve opening time 1000 µs
 Air pressure 0.50 bar
BioCAD Feed rate 10 mm/s
 Thickness 0.01 mm
HMI: human–machine interface; BioCAD: software to draw two-
dimensional (2D) patterns for printing of 3D structures.
Table 4. Printing Parameters to Fabricate 3D Dermal Models.
Model Component Software Parameter Value
BioInk HMI Dosing distance 0.05 mm
 Valve opening time 200 µs
 Air pressure 0.50–1.25 bar
 BioCAD Feed rate 10 mm/s
 Thickness 0.05 mm
Human primary dermal fibroblasts HMI Dosing distance 0.90 mm
 Valve opening time 250 µs
 Air pressure 0.25 bar
 BioCAD Feed rate 10 mm/s
 Thickness 0.01 mm
HMI, human–machine interface; 3D, three-dimensional.
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DNA damage caused by UV light. Dermis models were 
printed, and genomic DNA was isolated immediately after 
printing (day 0) and after 5 days of culture with the Wizard 
Genomic DNA Purification Kit (Promega, Fitchburg, WI) 
according to the manufacturer’s protocol. Each DNA sam-
ple (n = 3) was obtained from the processing of three differ-
ent and pooled dermal models. Fibroblast DNA content was 
measured at 260 nm with a NanoDrop (Fisher Scientific, 
Hampton, NH). As blanks, 3D models were produced by 
replacing cell suspension with sterile water. In parallel, 
genomic DNA was isolated from fibroblasts cultured in 2D 
with and without UV exposure for 10 min at an intensity of 
5 mW/cm2 (λ = 260 nm) to obtain positive and negative 
controls, respectively. The CPD detection was performed 
with the OxiSelect UV-Induced DNA Damage ELISA Kit 
(Cell Biolabs, San Diego, CA) following the manufactur-
er’s guidelines. The sample absorption was measured at 485 
nm with a microplate reader (FLUOstar OPTIMA; BMG 
Labtech, Ortenberg, Germany). The blank absorption val-
ues were subtracted from the cell samples’ absorption 
values.
Viability Tests
MTT assay. Printed dermal models were cultured up to 7 
weeks with medium changes every 2–3 days, and at specific 
time points (2 days, and 1, 2, 3, 4, 5, 6, and 7 weeks) the 
medium was replaced with 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT; Sigma-Aldrich) 1 
mg/ml in phosphate buffered saline (PBS). The samples 
were incubated for 3 h at 37 °C and 5% CO2. Only viable 
cells are able to reduce the MTT to insoluble formazan salts 
that stain cells blue, revealing their viability and distribu-
tion in the hydrogels. Samples were transferred in PBS for 
light microscopy analysis (Olympus 1X81 microscope 
equipped with the Olympus DP72 camera; Olympus, 
Tokyo, Japan).
PrestoBlue assay. The PrestoBlue assay (Life Technologies, 
Carlsbad, CA) was performed with printed models harbor-
ing human primary fibroblasts and with “blank” printed 
models (cell suspension substituted with sterile water). 
Samples were analyzed at days 1, 5, 8, 14, and 21 after 
printing. The models were subcultured and measured again 
after each assay time point. The PrestoBlue reagent is a 
resazurin-based solution containing a nonfluorescent cell-
permeable compound that turns fluorescent after being 
metabolized inside the cell. Only viable cells reduce the 
compound into the highly fluorescent resorufin. After each 
measurement, fresh medium was added, and the dermis 
models were subcultured while changing the medium every 
2–3 days. For analysis, the HDFa culture medium II was 
replaced with PrestoBlue Cell Viability Reagent (Life Tech-
nologies) diluted 1:10 in culture medium. The samples were 
incubated for 2 h at 37 °C and 5% CO2, and media fluores-
cence was measured in the FLUOstar OPTIMA reader at λex 
550 nm ± 10 nm and λem 590 nm ± 10 nm. The fluorescence 
readings [relative fluorescence values (RFVs)] of “blank” 
models were subtracted from the fluorescence values of 
dermal models. The test results were presented as a prolif-
eration trend of each single model during the culture period 
(Fig. 5A) and as the average of the actual change value 
(ACV) of each printed model for the different time points 
(Fig. 5B, where a = RFV samples day 5 – RFV samples 
day 1; b = RFV samples day 8 – RFV samples day 1; c = 
RFV samples day 14 – RFV samples day 1; and d = RFV 
samples day 21 – RFV samples day 1).
Collagen Type I ELISA
Human collagen type I was determined to evaluate the 
ECM production of fibroblasts in printed dermal models. 
Samples from culture supernatants were harvested for anal-
ysis at each medium change to calculate the amount of 
accumulation of produced collagen for up to 7 weeks. 
Figure 2. Scheme of the printing pattern in a layer-by-layer mode, as drawn by BioCAD software, for the generation of 3D dermal 
equivalents. The BioInk and the human primary fibroblasts were printed in an angular spiral pattern with dimensions of (A) 6×5.5 
mm for the BioInk solution and (B) 5×4.5 mm for the fibroblast suspension. The yellow arrow indicates the printing direction. (C) A 
circular pattern of 2.7 mm radius was drawn to print a cylindrical structure made of BioInk on top of the dermal model to provide a 
container for subsequent keratinocyte seeding.
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Collagen amount was correlated with metabolically active 
cells (PrestoBlue assay) populating the same printed dermis 
equivalents. Human collagen type I was determined using 
the MicroVue CICP EIA Kit (Quidel, San Diego, CA) 
according to the manufacturer’s instructions.
Full-Thickness Skin Model Production
Dermis equivalents were printed onto cell culture inserts and 
cultured in HDFa medium II for 7, 14, 21, and 42 days before 
human primary keratinocytes (HPEKs) were seeded on top to 
produce full-thickness skin models with dermal and epider-
mal parts. Before keratinocyte seeding, the HDFa medium II 
was completely removed from each well and from each cell 
culture insert. The gels were submerged in FTAL medium 
containing supplements (FTAL: Full-Thickness Air Lift; cus-
tom medium for full-thickness culture from CELLnTEC)  for 
2 h and were later exposed to air before seeding with kerati-
nocytes. The dermis was air-dried under the bench for 15 min 
to improve further keratinocyte attachment. The HPEKs 
were detached by trypsin–EDTA, and 10 µl of a cell concen-
tration of 107 cells/ml was seeded on top of each dermis 
model. The fibroblasts–keratinocytes–gels were incubated at 
37 °C and 5% CO2 for 45 min to allow HPEK adhesion onto 
the gels, then they were submerged in culture for 4–5 days, 
changing the culture medium (FTAL medium with supple-
ments) every 2–3 days. Cell culture inserts with the skin 
models were later transferred into petri dishes for further cul-
ture of the models up to 14 days at the air–liquid interface to 
induce keratinocyte differentiation into epidermis. Medium 
was changed three times per week.
Histological Analysis
Skin models harboring fibroblasts and keratinocytes were har-
vested after 14 days of culture at the air–liquid interface and 
were fixed in 10% neutral buffered formalin solution (Sigma-
Aldrich) for 3 h at room temperature (RT) in the fume hood. 
Models were embedded in Tissue-Tek cryomedium (Sakura 
Finetek Europe, Alphen, the Netherlands) before freezing at 
−80 °C. Sections of 8 µm were prepared with Cryostat Microm 
HM 550 (Microm International, Waldorf, Germany) and were 
fixed for 10 min at RT in acetone–methanol (1:1) solution, 
precooled at −20 °C, before staining.
Hematoxylin and eosin (H&E) staining. Cryosections were 
incubated with CAT hematoxylin (Biocare Medical, Con-
cord, CA) for 30 s, rinsed in tap water for 1 min, and incu-
bated further in tap water for 5 min. The sections were 
transferred in 75% and 96% ethanol (2 min per solution) 
and stained with eosin-Y (J.T.Baker Chemicals, Avantor 
Performance Materials, Center Valley, PA) for 4 min. The 
samples were thoroughly rinsed with tap water and observed 
by light microscopy. As a reference tissue, a skin model 
purchased from MatTek (EFT312; MatTek, Ashland, MA) 
was sectioned and H&E stained.
Immunohistochemistry. To analyze keratinocyte distribution 
in the printed skin models, the cryosections were stained with 
monoclonal mouse antibody specific for cytokeratins 1, 5, 
10, and 14 of the Moll catalog (Dako, Heverlee, Belgium). 
As positive controls, sections of epidermal models previ-
ously prepared according to protocols provided by CELLn-
TEC were used. Sections were incubated with antigen 
retrieval solution proteinase K (10 µg/ml in Tris–EDTA buf-
fer pH 9.0; Sigma-Aldrich) for 10 min at 37 °C and rinsed 
three times with Tris-buffered saline (TBS). Sections were 
processed following the instructions of the Starr Trek Univer-
sal HRP Detection System (Biocare Medical). Briefly, sec-
tions were blocked for 10 min at RT with the Biocare 
Background Sniper solution and were then incubated for 1 h 
at RT with the above-described primary antibody (dilution 
1:100 in TBS containing 1% bovine serum albumin). The 
sections were washed twice in TBS, incubated with 
Figure 3. Schematic representation of printed 3D dermal 
models. (A) A side view of the dermal equivalent is drawn with 
eight alternating BioInk spiral layers (gray lines) and seven cell 
suspension spiral layers (orange lines). This structure is topped 
with seven circular BioInk layers (gray dotted lines) forming 
a cylinder. (B) The dermis equivalent structure is presented 
visualizing the different layers. (C, D) An example of printed 
dermal equivalents directly after the printing process onto a cell 
culture insert. The cylindrical structure on top of the rectangular 
printed dermis is visible. Scale bar in (C) and (D): 2 mm.
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Peroxidazed 1 (Biocare Medical) for 5 min at RT to quench 
endogenous peroxidase, and rinsed again twice with TBS 
before 20 min incubation at RT with Trekkie Universal Link 
(Biocare Medical). Sections were washed twice with TBS, 
incubated with TrekAvidin–horseradish peroxidase (HRP) 
solution for 10 min at RT, and rinsed twice with TBS before 
5 min incubation with Betazoid DAB Chromogen (Biocare 
Medical) solution. Thereafter, sections were washed in tap 
water and counterstained with CAT Haematoxylin (Biocare 
Medical) for 30 s before another wash step in tap water and 
glycerol gelatin mounting (Sigma-Aldrich). The sections 
were analyzed by light microscopy.
Results
Cell Compatibility and Sterility of the Printing 
Process
A standardized procedure was established to assure high 
cell viability after the printing process. Human primary 
fibroblasts (HDFa) were automatically dispensed into tissue 
culture well plates according to printing parameters sum-
marized in Table 3, and viability was measured and com-
pared to that of manually seeded cells. The printing 
parameters did not affect cell viability. Printed cells showed 
a high viability of 96.70% ± 5.45% versus 99.40% ± 0.42% 
of the positive control as determined with a Cedex cell 
counter. Moreover, culturing HDFa under standard (2D) 
conditions for 14 days demonstrated that printed cells pre-
sented the same morphology and ability to proliferate as 
manually seeded cells.
Sterility of the cell-printing process with the 3DDiscovery 
bioprinter was verified by culturing printed fibroblasts in 
HDFa medium I (proliferation medium without antibiotics) 
in well plates for 14 days without contamination.
BioInk Printing Features
The developed BioInk is provided as a ready-to-use sterile and 
printable solution in 3 ml cartridges. BioInk is a PEG-based 
matrix that is polymerized on illumination at 365 nm to obtain 
a chemically cross-linked hydrogel. The combination of high 
viscosity and fast photopolymerization allows high shape 
fidelity. In Figure 3C and 3D, a dermis model was printed 
according to the scheme in Figures 3A and 3B, with alternat-
ing layers of BioInk and fibroblasts topped with an acellular 
cylinder of printed BioInk for later keratinocyte seeding. The 
printing process of the entire composite was 7 min and resulted 
in highly reproducible and stable BioInk structures.
Characterization of Printed 3D Dermis Models
Having confirmed the viability of printed cells and the ste-
rility of the printing process as well as the printability of the 
matrix, we further investigated the cytocompatibility of the 
BioInk. Human primary dermal fibroblasts were printed 
together with BioInk in alternating layers as shown in the 
scheme in Figure 3B to produce 3D dermal models (Fig. 
3C and 3D). To analyze cell viability and distribution inside 
the printed matrix, an MTT assay was performed after 2 
days of culture, as shown in Figure 4A. HDFa adhered to 
the BioInk with their typical morphology, remained viable, 
and were completely encapsulated in the hydrogel with the 
printing pattern still visible. Most of the printed fibroblasts 
spread inside the matrix, showing the cytocompatibility of 
the BioInk.
To verify the cell compatibility of the photopolymeriza-
tion process using UV light at a wavelength of 365 ± 10 nm, 
a CPD ELISA test was performed. The use of UV light to 
polymerize the BioInk to produce tissue-like structures is 
essential, but cells are prone to DNA damage (mainly CPD 
formation) after UV exposure. Light exposition time and 
distance play fundamental roles for UV damage. Therefore, 
DNA integrity was assessed. Dermis models were printed, 
and genomic DNA of the encapsulated human dermal fibro-
blasts was isolated to analyze any CPD formation. Figure 
4B shows the results obtained from analyzing the DNA iso-
lated from printed dermal models directly after printing and 
after 5 days of incubation. As positive control for CPD for-
mation, fibroblast cell suspension was exposed to UV light 
at 5 mW/cm2 and 260 nm wavelength. Cells in the printed 
models, independent of the time point analyzed, showed 
similar absorbance readings compared to the 2D negative 
control, in which fibroblasts were not exposed to UV light 
(Fig. 4B).
To investigate if the developed matrix could support not 
only fibroblast adhesion and spreading but also cell prolif-
eration, 3D dermal models were printed and analyzed for up 
to 21 days with PrestoBlue Cell Viability Reagent. Five der-
mal models were printed, and proliferation was assessed in 
each model five times during the culture period. As nega-
tive control, BioInk structures were printed without cells. 
As shown in Figure 5A, the assay demonstrated that fibro-
blasts encapsulated in BioInk remained viable and prolifer-
ated for up to 3 weeks with increasing values of proliferation. 
The assay demonstrated a significant difference of the met-
abolically active cells and consequently of the cell number 
printed per model (see Fig. 5A; fluorescence measurement 
at day 1 for each model). The fluorescence reading and con-
sequently the cell number at day 1 in each printed model 
increased in the same sequence as the order in which the 
models were printed (day 1: model 1, 2480.30 ± 150.18 
RFV; and model 5, 16027.90 ± 112.66 RFV). Although the 
initial cell number printed per model was not constant, the 
human primary fibroblasts were proliferating in the 3D 
printed BioInk structures throughout the time of the experi-
ment (Fig. 5A). Interestingly, when averaging the ACVs of 
each printed model for the different time points, the models 
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revealed a similar increase in proliferation as shown in 
Figure 5B. The models seeded with fibroblasts, unlike the 
blank structures (models without cells), remained stable for 
the entire culture period analyzed.
In our study, printed dermal models were cultured for up 
to 7 weeks containing viable fibroblasts that were populat-
ing the entire printed scaffold as verified by MTT assay 
(Fig. 6B). In Figure 6A, an MTT-stained whole printed der-
mal model cultivated for 2 days is shown. The printing 
pattern was still visible, and the cells were spreading, con-
firming the results shown in Figure 4A. The fibroblasts 
inside the printed BioInk structure were not only proliferat-
ing but also producing their own ECM, as verified by the 
secretion in the culture medium of C-terminal of type I col-
lagen peptide (CICP). Figure 6C shows the accumulated 
total protein amount increase during a culture time period of 
7 weeks. The enhanced collagen I expression correlates 
with the increased cell proliferation inside the printed mod-
els as verified with PrestoBlue analysis. These findings 
confirm the biocompatibility of the PEG-based hydrogel 
and show its suitability for long-term 3D cultures.
Characterization of Printed 3D Skin Models
To develop a printed skin model harboring dermal and epider-
mal parts on top, we analyzed whether keratinocytes seeded 
onto the dermal models were able to adhere, proliferate, and 
eventually differentiate into a stratified epidermis. Dermal 
models were printed and cultured for 7, 14, 21, and 42 days 
before being seeded with human primary epidermal keratino-
cytes (HPEKs). Subsequently, the skin models were sub-
merged in culture for 4–5 days prior to culturing at the 
air–liquid interface for 14 days to induce keratinocyte differen-
tiation. During this incubation period, the cells in the models 
were fed solely from the bottom of the cell culture insert, lead-
ing to a reduction of model thickness in the first 5 days of air–
liquid interface culture (data not shown). The models were 
fixed and prepared for cryosectioning before performing H&E 
Figure 4. Cell-compatible printing process. Human dermal 
fibroblasts were printed in a layer-by-layer mode with 
BioInk according to the printing scheme in Figure 3A. (A) 
Cell viability inside the printed structure was analyzed with 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) viability staining after 2 days of culture. The blue signals 
represent viable cells aligned in the printed pattern. In addition, 
the microscopic image shows distribution and spreading of the 
fibroblasts. Scale bar: 200 µm. (B) Potential DNA damage of the 
ultraviolet (UV) polymerization step during printing was assessed 
by cyclobutane pyrimidine dimer (CPD) quantitation. Genomic 
DNA from printed dermal models was isolated immediately 
after printing (day 0) and after 5 days of culture (day 5). 
Printed models without cells were used as blanks. As controls, 
genomic DNA isolated from fibroblasts without (negative 
control) and with exposure for 10 min to UV light (5 mW/cm2 
and 260 nm; positive control) were used. DNA samples were 
analyzed by enzyme-linked immunosorbent assay (ELISA), and 
the samples’ absorption was measured at 485 nm. The blank 
absorption values were subtracted from the absorption values 
of cell samples’ ELISA. Data show mean ± SD for triplicate 
DNA samples; three different dermal models were printed and 
collected for each DNA sample (B).
Figure 5. Viability and growth analysis of printed dermal models harboring human primary fibroblasts. (A) Each printed model was 
analyzed with PrestoBlue reagent to quantitatively determine metabolically active cells at days 1, 5, 8, 14, and 21. (B) The proliferation 
rate increase among the five culture time points of five independent dermis equivalents is shown. The relative fluorescence values 
(RFVs) were calculated from the mean of the actual change values (ACVs) of all models (n = 5). The RFV of the day 1 sample was set 
as a reference value for each model and was subtracted from the RFV of each sample at each time point (a = RFV samples day 5 – RFV 
samples day 1; b = RFV samples day 8 – RFV samples day 1; c = RFV samples day 14 – RFV samples day 1; d = RFV samples day 21 – 
RFV samples day 1).
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staining on 8 µm slices to analyze their structure. Figure 7 
shows H&E staining of skin models for which the dermal parts 
were cultivated for (B) 7, (C) 14, (D) 21, and (E and F) 42 days 
prior to keratinocyte seeding. The skin models were populated 
with many cells (blue nuclei). Eosin-stained structures (red) 
were distributed all over the skin models of dermal parts that 
were cultivated for 14, 21, and 42 days prior to keratinocyte 
seeding (Fig. 7C–7E; see arrows).
A clear stratum corneum was visible in the skin models of 
dermal equivalents that were cultured for 6 weeks prior to 
keratinocyte seeding (Fig. 7F), whereas no epidermal layers 
developed in the earlier experimental conditions. For compari-
son, a commercially available skin model from MatTek 
(EFT312) was H&E stained, showing a well-differentiated 
stratified epidermis on top of the dermal part (Fig. 7A).
Cryosections of the printed skin models were further 
stained for cytokeratins solely expressed by keratinocytes 
to distinguish between dermal and epidermal layers. The 
antibody is specific for cytokeratins 1, 5, 10, and 14 of the 
Moll catalog. As a positive control, an epidermal model 
produced according to protocols published by CELLnTEC 
was used (Fig. 8B). In Figure 8A, raised epidermal models 
were stained without primary antibody to determine 
background levels of the staining (negative control). The 
antibody was specific for the epidermis visualized with the 
distinct brown staining (Fig. 8B). Cell nuclei were counter-
stained with hematoxylin to appear as blue points. We could 
demonstrate that the red (eosinophilic) structures previ-
ously detected by H&E staining inside the dermis (Fig. 7) 
were groups of keratinocytes (Fig. 8D and 8E). In these 
conditions, the cells were not able to build an epidermis. In 
contrast, dermis cultured for longer times (e.g., 21 and 42 
days) showed keratinocytes located on the surface, and a 
distinct epidermis, although not completely differentiated, 
was detectable (Fig. 8 F–H). These results showed a corre-
lation between printed dermal culture incubation prior to 
keratinocyte seeding and epidermis formation. With time, 
keratinocyte migration into the printed dermis was decreased 
or even halted. The stratum corneum was clearly detectable 
on top of the model with the longest pre-incubation time of 
the dermis (Fig. 8G and 8H).
Discussion
The bioprinting technology offers tremendous potential to 
produce reliable and complex organotypic tissue models for 
Figure 6. Long-term cultivation 
of printed dermis equivalents. (A) 
An entire printed dermal model is 
shown after 2 days of incubation 
and later 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide 
(MTT) staining (viability stain). The 
printing pattern is visible after the 
short culture period, unlike in (B), 
where the printed dermal model 
was incubated for 7 weeks and 
afterward MTT stained. The blue 
signals are viable cells. In addition, cell 
distribution and spreading within the 
printed structure are visible. Scale bar: 
(A) 1 mm; (B) 200 µm. (C) Collagen 
type I production of printed dermal 
models is assessed by measuring 
C-terminal of type I collagen peptide 
(CICP) in the supernatant with 
enzyme-linked immunosorbent 
assay (ELISA). The accumulated 
total protein amount increases 
with time. Metabolically active cells 
were quantitatively determined with 
PrestoBlue reagent at the same time 
points as the ELISA measurements. 
Data show mean ± SD for triplicate 
samples.
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drug development and regenerative medicine.5–6,27 Different 
bioprinting technologies to deposit cells with high viability28 
as well as printable ECM-like hydrogels to support cell 
growth in 3D are available.9,27 However, at the moment, the 
bioprinting approach faces several shortcomings. Most 
printed tissue models are produced with in-house developed 
bioprinters, limiting the reproducibility and transferability of 
the achievements to other research groups or industries.29–30 
Furthermore, commercialized bioinks are hardly available. 
Researchers active in this field must rely on biocompatible 
hydrogels, such as alginate, agarose, fibrinogen, collagen I, 
and matrigel, that have been proven valuable tools for cultur-
ing cells in 3D but are not optimized for printing applica-
tions.10 An optimal bioink should provide not only a 
cell-compatible environment but also a high viscosity to print 
high-fidelity structures that are polymerized instantaneously 
after the printing process.30 For this purpose, polymers, such 
as hyaluronic acid, dextran, or gelatin, are functionalized 
with acrylate–methacrylate groups to make them susceptible 
for photo-induced polymerization.29,31–33 Although these 
novel synthesized polymers show improved printing proper-
ties, the lack of a standardized production protocol hampers 
further industrial applications.
One of the first commercialized 3D bioprinters was pro-
vided by EnvisionTEC GmbH (Marl, Germany) and was used 
in many different studies.33–35 The instrument can process a 
variety of bioinks with light-, ionic-, or thermal-induced 
Figure 7. Hematoxylin and eosin (H&E) staining of printed skin 
models. (A) A skin model purchased from MatTek (EFT312) as 
reference tissue was H&E stained. Printed dermal models were 
cultured for (B) 7, (C) 14, (D) 21, and (E and F) 42 days before 
keratinocyte seeding. The models were then cultured for 5 days 
submerged and for 14 days at the air–liquid interface before 
cryosectioning and H&E staining. The black arrows indicate the 
presence of eosinophilic bodies and structures inside as well as 
on the surface of dermal models. (F) Epidermis-like structures 
on top of the dermal part are visible. The nuclei are blue;  
the cytoplasm and eosinophilic structures are pink. Scale bar 
(A): 100 µm; (B–F): 50 µm.
Figure 8. Immunohistological staining of printed skin models. 
Dermal equivalents were printed and cultured for (C and 
D) 7, (E) 14, (F) 21, and (G and H) 42 days prior to seeding 
with human primary keratinocytes on top. The models were 
cultured for 5 days submerged and 14 days at the air–liquid 
interface. After cryosectioning, the tissues were stained with 
anti-pankeratin antibody, labeling the cytokeratins 1, 5, 10, and 
14 (Moll catalog). (A) The negative control (without primary 
antibody); and (B) the positive control of in vitro epidermal 
models (epidermal models were produced with the kit from 
CELLnTEC). (C) The negative control of printed skin models 
(without primary antibody). The longer the printed dermis is 
cultured prior to keratinocyte seeding, the better the epidermal 
structure develops on top of the dermis. Cytokeratins are 
stained brown, and cell nuclei are blue after hematoxylin 
counterstaining. Scale bar: 50 µm.
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polymerization modes. To print under sterile conditions, the 
bioprinter is placed in the laminar flow bench.
The company Organovo Holdings (San Diego, CA) 
together with the company Invetech (Melbourne, Australia) 
developed a novel bioprinter capable of printing living tis-
sues for medical research and therapeutic applications.17,36–37 
The company provides a service to produce tissues from dif-
ferent cell types with their proprietary printing technology. 
The bioink consists of a “cellular paste” made of single or 
multiple cell types. This bioink is extruded in tissue-specific 
geometries together with sacrificial bioinks (e.g., agarose) as 
support material that is later removed to generate, for exam-
ple, vascular structures with lumens.17 After the printing pro-
cess, the cells rearrange into a tissue-like structure.17
In this work, we developed a holistic bioprinting approach, 
including (1) a commercialized bioprinter enclosed in a flow 
box for sterile tissue fabrication with a user-friendly software 
BioCAD, a photopolymerization unit (UV-LED; λ = 365 nm ± 
10 nm), and cell-compatible printheads; and (2) a commercial-
ized ready-to-use photopolymerizable BioInk. This all-in-one 
solution is supplemented with a standard operation procedure 
to generate printed soft tissue models. The inkjet-based print-
heads allow printing solutions in viscosities up to 1000 mPa . 
s. In a proof-of-concept study, a skin-like tissue model was 
printed as a soft tissue reference.
To produce skin equivalents, we used in our study human 
primary cells that, unlike cell lines, have the potential to 
fully differentiate into a stratified epidermis.38 However, 
primary cells are as well known to be more sensitive than 
cell lines.39 In standard skin equivalent production, fibro-
blasts are embedded in collagen I.40 Although collagen I is 
also used in other skin bioprinting approaches,24,26 we 
developed the BioInk as ECM-like matrix with improved 
printing properties and without batch-to-batch variations.41 
A cell suspension of human dermal fibroblasts was printed 
in alternating layers with BioInk in a predefined pattern as 
shown in Figure 3 to represent the dermal compartment. 
The fibroblasts in the printed dermis were viable and cul-
tured up to 7 weeks, thereby populating the entire printed 
structure. Despite the high sensitivity of primary cells, the 
established printing conditions as well as the developed 
BioInk turned out to be cell-friendly. In addition, the use of 
UV light to induce BioInk polymerization did not affect the 
DNA integrity of the fibroblasts as verified with analysis of 
CPD generation. UVA light (320–400 nm) is known to 
induce CPDs as well as double-strand breaks in skin tis-
sue.42–44 Moreover, fibroblasts not only were able to adhere, 
spread, and remain viable inside the constructs but also 
were proliferating as shown with viability tests for up to 42 
days. When comparing printed acellular with printed fibro-
blast-containing models, the cell-containing tissues were 
long-term stable, which can be attributed to the cells’ col-
lagen I expression leading to strengthening and remodeling 
of the printed structure. With respect to drug development, 
the feasibility for long-term cultures of organotypic models 
is an important aspect allowing repeated drug exposure to 
analyze chronic drug toxicity.45
Fundamental for epidermis formation is the initial adher-
ence of keratinocytes on the surface of the dermis to build a 
monolayer. To address this issue, Lee and coworkers24 were 
printing keratinocytes (HaCaT) in collagen I hydrogels to 
immobilize the cells on top of a dermal part. Using LaBP, 
Koch et al.25 transferred the keratinocytes previously 
embedded in collagen I hydrogels onto printed dermis. 
However, it is not reported whether the embedding of kera-
tinocytes into a matrix interferes with epidermis formation. 
In this study, a cylindrical structure, as shown in Figure 3, 
was printed with BioInk on top of the printed dermis to pro-
vide a container for keratinocytes seeding to prevent cell 
loss. Keratinocytes strongly depend on secreted factors and 
ECM produced from fibroblasts to properly differentiate 
into a stratified epidermis.46–48 Thus, printed dermal models 
were cultured for up to 7 weeks and were seeded with 
human dermal keratinocytes at different time points to 
determine the optimal seeding procedure. In the printed der-
mal models, ECM expression increased throughout culture 
time as verified with collagen type I expression. As 
expected, this finding correlated with improved cell attach-
ment and epidermis formation at later keratinocyte-seeding 
time points. In short-term cultivated dermal models, the 
keratinocytes tended to migrate into the dermis.
Despite these promising results in standardized bio-
printed organotypic tissue production, further optimization 
is necessary to transfer the process into industrial applica-
tions. In our study, a fully stratified epidermis as obtained 
with standard skin equivalent protocols using collagen I40 
was not achieved. Furthermore, the number of printed cells 
should be constant in each model to obtain standardized 
dermis equivalents. In our approach, fibroblast number 
increase during culture time was constant among the dermal 
models but not initial cell numbers. This problem is referred 
to as “cell sedimentation” during the printing process due to 
the static maintenance of cells in aqueous low-viscosity 
solutions. We are currently evaluating different stirring sys-
tems and velocities in our group to obtain a homogeneous 
and viable cell suspension during the entire printing pro-
cess. The sedimentation effect has also been described by 
Parsa et al.49 They introduced gentle agitation and surfac-
tant addition into the medium during printing to maintain 
the cells suspended and improve droplet integrity. Although 
a homogenous cell suspension was achieved, cell aggrega-
tion hindered extended printing times. Chahal et al.50 were 
increasing the viscosity of the cell suspension with Ficoll 
PM400 to obtain neutral buoyancy, thereby reducing cell 
sedimentation in the printing cartridge. In general, increas-
ing viscosity reduces cell sedimentation, thereby enhancing 
shear forces, which might have deleterious effects on the 
cells.51
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In our study, keratinocytes were seeded manually on top 
of the dermal constructs to precisely deposit the cells. The 
reason for manual cell pipetting was the lack of an optical 
system to, for example, exactly locate previously printed 
structures, allowing the manipulation of printed constructs 
after a certain culture time. This feature should be integrated 
in next-generation bioprinters and is under investigation in 
our lab. Efforts are also put into the development of cell-
type-specific bioinks that provide all the necessary cues for 
proper cell functioning.9 This results in extensive character-
ization and standardization of novel bioinks.9 The here-
developed BioInk showed compatibility with several cell 
lines and primary cells (data not shown) exhibiting univer-
sal properties.
In summary, although in bioprinting several technical 
and biological issues still need to be tackled, the work pre-
sented here will help in promoting this technology to find 
its way into routine industrial applications.
Conclusion
We have presented, for the first time, a bioprinting all-in-
one solution to produce a skin-like reference soft tissue 
model harboring human primary fibroblasts and keratino-
cytes. The established printing process and the developed 
BioInk are cell compatible and permit the generation of 
long-term culture models. Further optimization of our sys-
tem can potentially facilitate the complete standardization 
of 3D tissue model generation. Future advancements of this 
technology will rely on standardization of bioprinting 
devices and customized bioinks to promote proper cell 
function. Especially in the cosmetic industry, reliable in 
vitro skin models are urgently needed for the testing of cos-
metic ingredients as demanded by law in Europe. Also in 
drug development, the production of 3D tissue equivalents 
with bioprinting exhibits a huge potential. Especially, long-
term culture of in vitro tissue models is of interest to moni-
tor the effects of multiple drug administration. Furthermore, 
regenerative medicine will benefit from the bioprinting 
technology because it offers the possibility to reproduce tis-
sue and organ complexity in vitro. The implementation of a 
vasculature system into the printed tissue will allow the pro-
duction of larger tissues.
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